Zeuzem et al., 2015 - Google Patents
Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a …Zeuzem et al., 2015
View PDF- Document ID
- 4468021119940354014
- Author
- Zeuzem S
- Ghalib R
- Reddy K
- Pockros P
- Ari Z
- Zhao Y
- Brown D
- Wan S
- DiNubile M
- Nguyen B
- Robertson M
- Wahl J
- Barr E
- Butterton J
- Publication year
- Publication venue
- Annals of internal medicine
External Links
Snippet
Background: Novel interferon-and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection. Objective: To evaluate the safety and efficacy of grazoprevir (NS3/4A protease inhibitor) and elbasvir (NS5A inhibitor) in treatment-naive patients. Design …
- 201000009910 diseases by infectious agent 0 title abstract description 55
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zeuzem et al. | Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial | |
Falade-Nwulia et al. | Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review | |
Everson et al. | Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial | |
Burstow et al. | Hepatitis C treatment: where are we now? | |
Stedman | Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential | |
Dore et al. | Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial | |
Armstrong et al. | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | |
Bacon et al. | Boceprevir for previously treated chronic HCV genotype 1 infection | |
Backus et al. | Comparative effectiveness of ledipasvir/sofosbuvir±ribavirin vs. ombitasvir/paritaprevir/ritonavir+ dasabuvir±ribavirin in 6961 genotype 1 patients treated in routine medical practice | |
Sherman et al. | Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy | |
Backus et al. | Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large US cohort | |
Rose et al. | Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection | |
Alao et al. | Baseline intrahepatic and peripheral innate immunity are associated with hepatitis C virus clearance during direct‐acting antiviral therapy | |
Chang et al. | Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease | |
Meissner | Update in HIV–hepatitis C virus coinfection in the direct acting antiviral era | |
Weisberg et al. | A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection | |
Childs-Kean et al. | Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C | |
Re III et al. | Determinants of liver complications among HIV/hepatitis B virus–coinfected patients | |
Machado et al. | Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study | |
Florian et al. | Direct‐acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now | |
Lagging et al. | Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations | |
Jaroszewicz et al. | Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA | |
Łucejko et al. | Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection | |
Rosenthal et al. | Sofosbuvir and ledipasvir for HIV/HCV co-infected patients | |
Ogawa et al. | Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C |